Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M010821200 on September 14, 2001

J. Biol. Chem., Vol. 276, Issue 47, 43723-43733, November 23, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/47/43723    most recent
M010821200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kretz-Remy, C.
Right arrow Articles by Arrigo, A.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kretz-Remy, C.
Right arrow Articles by Arrigo, A.-P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

NFkappa B-dependent Transcriptional Activation during Heat Shock Recovery

THERMOLABILITY OF THE NF-kappa B·Ikappa B COMPLEX*

Carole Kretz-Remy, Béatrice Munsch, and André-Patrick ArrigoDagger

From the Laboratoire Stress Oxydant, Chaperons, et Apoptose, Centre de Génétique Moléculaire et Cellulaire, CNRS-UMR 5534, Université Claude Bernard Lyon I, F-69622 Villeurbanne Cedex, France

Received for publication, November 30, 2000, and in revised form, September 10, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Heat shock induces the accumulation of misfolded proteins and results in the preferential expression of heat shock proteins, which help the cell to recover from thermal damage. Heat shock is a well known transcriptional activator of the human immunodeficiency virus type 1 long terminal repeat (LTR). We report here that mutations or deletions of the LTR kappa B sites impaired the LTR transcriptional activation by heat shock. Further analysis revealed that, during heat shock recovery, the NF-kappa B p65 and p50 subunits migrated into the nucleus of HeLa cells, bound to DNA, and induced kappa B-dependent reporter gene expression. This NF-kappa B activation did not depend on new transcriptional and/or translational events and on the pro-oxidant state generated by heat shock. It was not concomitant with Ikappa Balpha phosphorylation and was not abolished by the expression of Ikappa B kinase or Ikappa Balpha dominant-negative mutants. Moreover, NF-kappa B activation and migration into the nucleus were not concomitant with Ikappa Balpha /beta or p105 degradation. However, during heat shock recovery, NF-kappa B was dissociated from its complexing partners, allowing its migration into the nucleus. Hence, we describe here a novel mechanism for activation of NF-kappa B based on the thermolability of the NF-kappa B·Ikappa B complex.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The human immunodeficiency virus type 1 (HIV-1)1 long terminal repeat (LTR) contains a complex eukaryotic promoter that regulates the transcription of the provirus (9). The progression of the disease induced by HIV-1 infection is directly correlated with the level of expression of HIV-1 RNA (10-12). Hence, modulation of HIV-1 LTR activity is a key element in the development of the disease. The HIV-1 promoter contains binding sites for many transcription factors such as NF-kappa B, SP1, upstream stimulatory factor, and AP1 and therefore confers on the virus the possibility of being activated or reactivated by many stimuli (13, 14). Among these stimuli are cytokines, phorbol esters, tumor promoters, and protein kinase inhibitors (15), co-infection by other viruses (1), and oxidative (16) or thermal (17-19) stress. If, for oxidative stress mediated by H2O2 or tumor necrosis factor-alpha (TNF-alpha ), the intervention of the transcription factor NF-kappa B in the transcriptional activation of the LTR was clearly demonstrated (16), the mechanism regulating the thermal activation of this promoter is still unknown.

Heat shock generates abnormally folded proteins. As a consequence, the expression of most genes is inhibited, whereas a small set of genes (the heat shock genes) are preferentially transcribed. Heat shock genes encode heat shock or stress proteins that can protect cells from thermally induced injuries. Indeed, heat shock proteins act as molecular chaperones that help the cells to cope with aberrant protein folding and, as a consequence, help the cell to recover from thermal damage (20). Several studies suggested that a modification of the redox state homeostasis and particularly of the non-protein thiols such as glutathione could be involved in the heat stress signal transduction pathway that activates heat shock protein synthesis (21-24). Indeed, hydrogen peroxide treatment can induce, in vitro and in vivo, heat shock gene transcription (25, 26) by activating heat shock transcription factor-1 (27, 28). Of interest, amino acid analogs, which are powerful agents that disrupt protein folding, are able to induce NF-kappa B activation (2). This observation, together with the fact that NF-kappa B activation is under the control of the intracellular redox state (29, 30), prompted us to investigate the mechanism of NF-kappa B activation by heat shock.

NF-kappa B belongs to the Rel/NF-kappa B family of transcription factors that includes many proteins conserved from Drosophila to humans. It controls a variety of physiological aspects of immune, inflammatory, viral, and stress responses (31). NF-kappa B is a heterodimeric (p65/p50) inducible factor whose regulation is centered around nuclear-cytoplasmic shuttling. Indeed, the transcription factor is retained in a latent form in the cytoplasm of unstimulated cells by inhibitory molecules called Ikappa B subunits (Ikappa Balpha , Ikappa Bbeta , and Ikappa Bepsilon or p50 and p52 precursors called p105 and p100, respectively) (32-35). Ikappa B subunits inhibit NF-kappa B by masking its nuclear localization signal, thereby causing its cytoplasmic retention and blocking both its DNA binding and transactivation ability (36-39). Migration of NF-kappa B into the nucleus requires cytoplasmic NF-kappa B·Ikappa B complex disruption. Most NF-kappa B inducers such as inflammatory cytokines (e.g. TNF-alpha ), phorbol esters (e.g. phorbol 12-myristate 13-acetate), pathogenic agents, and oxidative stress (31) act via a common pathway based on the phosphorylation-induced degradation of Ikappa B proteins, which was first described with the best studied and major Ikappa B protein, Ikappa Balpha . Stimuli induce Ikappa Balpha phosphorylation at Ser32 and Ser36 by the Ikappa B kinase (consisting of IKKalpha , IKKbeta , and IKKgamma ) (4, 6, 40-44). This step triggers multi-ubiquitination at Lys21 and Lys22 of Ikappa Balpha , which then signals Ikappa Balpha for degradation by the 26 S proteasome (45-48). Following Ikappa Balpha degradation, NF-kappa B migrates into the nucleus as an active factor and induces transcription of kappa B-containing genes such as the Ikappa Balpha gene. Newly synthesized Ikappa Balpha enters the nucleus, removes NF-kappa B dimers from DNA, and causes their exportin-mediated transport to the cytoplasm (49, 50). To date, three exceptions to this universal pathway of NF-kappa B activation have been reported. Activation of NF-kappa B in response to UV radiation or amino acid analog treatment depends on Ikappa Balpha degradation, but without its prior phosphorylation (2, 51, 52). In contrast, anoxia stimulates Ikappa Balpha Tyr42 phosphorylation, a phenomenon that leads to p65/p50 release from the NF-kappa B·Ikappa Balpha complex (53).

We report here that heat shock induces the transcriptional activation of the HIV-1 LTR through a mechanism that is NF-kappa B-dependent. NF-kappa B activation that occurs during the heat shock recovery period differs from the universal pathway of NF-kappa B activation since it does not involve any prior phosphorylation or degradation step of Ikappa B subunits. Moreover, this phenomenon does not require new transcriptional and/or translational events and is a redox-independent process. During heat shock recovery, we observed a dissociation of NF-kappa B from its complexing partners, allowing NF-kappa B to migrate into the nucleus. This new mechanism of NF-kappa B activation is characterized by the thermolability of the NF-kappa B·Ikappa B complex.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Cultures-- HeLa cells were grown at 37 °C in the presence of 5% CO2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. For heat shock treatments, the cells were incubated in Dulbecco's modified Eagle's medium and 10% fetal calf serum supplemented with 25 mM HEPES, pH 7.4.

Reagents and Plasmids-- Pyrrolidine dithiocarbamate (PDTC), N-acetyl-L-cysteine (NAC), hydrogen peroxide, and type B gelatin were from Sigma (Saint Quentin Fallavier, France). Recombinant human TNF-alpha was purchased from Pepro Tech EC Ltd. (London, United Kingdom). Anti-p50 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) is a goat polyclonal antibody (C-19) reactive with p50 and p105 proteins of human origin. Anti-p52 antibody (Santa Cruz Biotechnology) is a rabbit polyclonal antibody (K-27) specific for p52 and p100 proteins of human origins. Anti-Ikappa Balpha /MAD-3 antibody (Santa Cruz Biotechnology) is a rabbit polyclonal antibody raised against a full-length recombinant protein of human Ikappa Balpha . Rabbit anti-p65 polyclonal antibody (Upstate Biotechnology, Inc., Lake Placid, NY) is directed against the 13 C-terminal amino acids of the p65 subunit of human NF-kappa B. The wild-type HIV LTR-Cat plasmid was a kind gift from Dr. F. Arenzana-Seisdedos (Pasteur Institute, Paris, France). It is composed of a 719-base pair XhoI-HindIII fragment containing the HIV-1 LTR (from the pBenn-Cat plasmid (1)) in front of the cat gene of pIBI20 (International Biotechnologies Inc.). The (Delta kappa B)HIV LTR-Cat plasmid was obtained by deleting a 26-base pair fragment containing the two kappa B sites of the wild-type plasmid. The pLTR-Cat-wt and pLTR-PstI plasmids were described elsewhere (2). pLTR-Cat-EcoRI is identical to pLTR-Cat-wt, except that the two kappa B consensus sequences were mutated into two perfect palindromic kappa B sites. These mutants were produced by megaprimer polymerase chain reaction mutagenesis (3). The pLTR-Cat-NcoI plasmid is a mutation of the pLTR-Cat-wt plasmid in which the kappa B sites and the three SP1 sites of the LTR were spaced out by the insertion of a 4-nucleotide sequence (CCAT). The p2xkappa B-37TKcat vector, which is composed of two kappa B sites in front of a cat reporter gene, has already been described (2). pN-FLAG-CHUK(K44A) is a pRK7-S/N vector containing the full-length open reading frame of human IKKalpha cDNA with an alanine substitution of the conserved lysine residue at position 44. The expression of pN-FLAG-CHUK(K44A) leads to a dominant-negative mutant of IKKalpha kinase (4). The pRK5-IKKbeta (K44A)-C-FLAG plasmid is the pRK5-C-FLAG vector containing the IKKbeta cDNA encoding amino acids 1-755 with an alanine substitution of the conserved lysine residue at position 44. pRK5-IKKbeta (K44A)-C-FLAG encodes a dominant-negative mutant of IKKbeta kinase (4-6). pLXSN and pLXSN-Ikappa Balpha M were described elsewhere (7). The expression of pLXSN-Ikappa Balpha M leads to a dominant-negative mutant of Ikappa Balpha in which the N-terminal (Ser32 and Ser36) and C-terminal (Ser283, Ser288, Ser291, Ser293, and Ser296) serine phosphorylation sites are mutated to alanines (7).

Transfection and CAT Assays-- HeLa cells were seeded the day before transfection at a density of 2 × 106 cells/100-mm dishes. The cells were then transfected with 11 µg of the desired plasmids according to the LipofectAMINETM reagent procedure (Life Technologies, Inc., Cergy Pontoise, France). The lipid·DNA complex was applied to the cultured cells over 4 h. Two h later, cells were trypsinized and replated onto five or six 60-mm dishes. After 12 h, the cells were submitted to various heat, hydrogen peroxide, or TNF-alpha treatments and harvested after a 24-h recovery period. The transfected cells were then lysed, and 50 µg of total cellular proteins were analyzed using the CAT/enzyme-linked immunosorbent assay test (Roche Molecular Biochemicals, Meylan, France) according to the manufacturer's instructions.

Indirect Immunofluorescence Analysis-- HeLa cells were grown on glass coverslips coated with 0.1% type B gelatin. Twenty h later, the cells were submitted to various heat treatments at 43 °C, followed or not by a recovery period at 37 °C. Thereafter, the cells were rinsed with phosphate-buffered saline and fixed for 90 s with cold methanol. Anti-p65 antibody was diluted 1:100 in phosphate-buffered saline supplemented with 0.1% bovine serum albumin. Isothiocyanate-coupled goat anti-rabbit immunoglobulin (Organon Teknica-Cappel, Fresnes, France) was used as a second antibody. The stained cells were observed and photographed with a Zeiss Axioskop photomicroscope. Fluorescent images were recorded on Tri-X Pan film (Eastman Kodak Co.).

NF-kappa B p65 Transcription Factor Assay-- NF-kappa B binding to kappa B sites was assessed using the Trans-AMTM NF-kappa B p65 transcription factor assay kit (Active Motif Europe, Rixensart, Belgium). In this assay, an oligonucleotide containing the NF-kappa B consensus site is attached to a 96-well plate. The active form of NF-kappa B contained in cell extracts specifically binds to this oligonucleotide and can be revealed by incubation with antibodies using enzyme-linked immunosorbent assay technology with absorbance reading. In our study, HeLa cells were submitted to various heat treatments. Thereafter, whole cell extracts were prepared, and 10 µg of total cellular proteins were analyzed for p65 binding to kappa B oligonucleotide according to the manufacturer's instructions. Note that for whole cell extract preparation, a sonication step of 20 s was added after the 10-min incubation time in lysis buffer. Specificity of the assay was monitored by competition with free wild-type kappa B consensus oligonucleotide or mutated kappa B consensus oligonucleotide according to the manufacturer's instructions.

Gel Electrophoresis, Immunoblotting, and Co-immunoprecipitation-- Acrylamide (10%) gel electrophoresis and immunoblotting were performed as described (2). For co-immunoprecipitation, 5 × 106 cells were resuspended in 500 µl of IPP 150 buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.05% Nonidet P-40) and 20 µl of cØmpleteTM protease inhibitor mixture (Roche Molecular Biochemicals). The cells were lysed by repeated freezing-thawing (three times). After centrifugation for 10 min at 4000 × g, the supernatant was incubated for 3 h on ice with 1 µg of nonimmune or anti-Ikappa Balpha serum (for p65/Ikappa Balpha co-immunoprecipitation) or with 3 µg of nonimmune or anti-p65 serum (for p65/p100 co-immunoprecipitation). The immunocomplexes were precipitated with protein A-Sepharose with constant agitation at 4 °C for 1 h. Thereafter, the protein A immunocomplexes were centrifuged at 4000 × g for 5 min, washed several times with cold IPP 150 buffer, and boiled in SDS sample buffer. After removal of protein A-Sepharose by centrifugation, samples were analyzed by SDS-polyacrylamide gel electrophoresis and immunoblotted with either anti-p65 or anti-p100 antibody.

Gel Filtration Analysis-- Cells (2 × 107) were resuspended in 1 ml of IPP 150 buffer and lysed by repeated freezing-thawing (three times). After a 10-min centrifugation at 4000 × g, the supernatant was applied to a Sepharose 6B gel filtration column (1 × 100 cm; Amersham Pharmacia Biotech, Ullis, France) equilibrated and developed in 20 mM Tris-HCl, pH 7.4, 20 mM NaCl, 5 mM MgCl2, and 0.1 mM EDTA. The fractions eluted from the column were analyzed by immunoblotting. Molecular mass markers (Sigma) that were used to calibrate the gel filtration column included dextran blue (2000 kDa), thyroglobulin (669 kDa), apoferritin (443 kDa), beta -amylase (200 kDa), alcohol dehydrogenase (150 kDa), bovine serum albumin (66 kDa), and carbonic anhydrase (29 kDa).

In Vivo Fluorescent Measurement of Intracellular Reactive Oxygen Species-- ROS detection was performed by ethidium bromide fluorescence as already described (8). Briefly, 1.5 × 106 cells pretreated or not with PDTC or NAC were submitted to various heat treatments. Cells were trypsinized and resuspended in phosphate-buffered saline containing 40 µg/ml hydroethydine, the sodium borohydride-reduced form of ethidium bromide. Flow cytometric analysis was performed with a FACSCalibur cytometer (Becton Dickinson, Le Pont de Claix, France) using a 488-nm excitation wavelength. The emission filter was 610 nm for oxidized hydroethydine fluorescence.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Heat Shock Induces kappa B-site-dependent Transcriptional Activation of the HIV-1 LTR-- We previously reported that the HIV-1 LTR was transcriptionally activated in response to heat shock (19), but the mechanism regulating this thermal activation remained obscure. To unravel the molecular mechanism of this activation, we tested the heat-induced transcriptional activity of the wild-type or kappa B-deleted HIV-1 LTR. HeLa cells were transiently transfected with the wild-type HIV LTR-Cat or (Delta kappa B)HIV LTR-Cat plasmid and thereafter submitted to 90-min heat shock treatments performed at temperatures ranging from 41 to 44 °C. In these experiments, the transfection efficiency (determined in a parallel transfection using the beta -galactosidase gene-bearing plasmid pCMVbeta ) was ~90%. By quantifying the level of CAT polypeptide produced, we observed that up to 43 °C, the different heat shock treatments stimulated the transcriptional activity of the wild-type HIV-1 LTR (Fig. 1, A-D). At 44 °C, a drastic decrease in CAT polypeptide production was observed. In contrast, deletion of the two kappa B sites of the HIV-1 LTR completely abolished HIV-1 LTR activation by heat shock (Fig. 1A). These results indicate that the HIV-1 LTR transcriptional response to a heat stress is kappa B site-dependent.


View larger version (30K):
[in this window]
[in a new window]
  		Fig. 1.   kappa B sites are indispensable for HIV-1 LTR transcriptional activation by heat shock. HeLa cells were transiently transfected with the wild-type (wild-type HIV LTR-Cat; black bars) or kappa B-deleted ((Delta kappa B)HIV LTR-Cat; gray bars) HIV-1 LTR-cat reporter construct (A) or with vectors containing the wild-type LTR (pLTR-Cat-wt; B-D, black bars), pLTR-Cat-PstI (B, gray bars), pLTR-Cat-EcoRI (C, gray bars), or pLTR-Cat-NcoI (D, gray bars). Cells were subsequently heat-shocked for 90 min at temperatures ranging from 41 to 44 °C. After a 24-h recovery period at 37 °C, the level of cytoplasmic CAT enzyme was quantified by the enzyme-linked immunosorbent assay as described under "Experimental Procedures." The results are presented as -fold stimulation, which was calculated as the ratio of the CAT concentration of the different samples to that of the control unstressed cells. The histograms shown are representative of four independent and identical experiments. The DNA sequences of the wild-type and mutated HIV-1 LTRs are shown in E. Mutations are shown in underlined boldface letters.

We therefore investigated the effect of different nucleotide variations in the sequence of the two kappa B sites present in the HIV-1 LTR. The kappa B consensus sequence (5'-GGGA(N/N)YYCC-3') is highly conserved. However, small nucleotide variations have been described to occur preferentially at the level of the 4 central nucleotides (54). The pLTR-Cat-PstI mutant (Fig. 1E) was constructed by modifying the most conserved 5'-nucleotides (GG) of the kappa B sites with CA nucleotides. These mutations have been described to impair the transcriptional activity of the HIV-1 LTR after UV irradiation or mitogen treatment (55, 56). In the pLTR-Cat-EcoRI mutant, the two kappa B sites were transformed into palindromic kappa B sites (Fig. 1E), a situation that is suspected to improve the activity of NF-kappa B (54, 57). These constructions were transfected into HeLa cells, which were submitted thereafter to heat shock treatments. A complete impairment of the HIV-1 LTR response to heat shock was obtained in the case of pLTR-Cat-PstI (Fig. 1B), as was obtained with the kappa B-deleted vector (Fig. 1A), suggesting that kappa B sites are indispensable for HIV-1 LTR activation by heat shock. The pattern of pLTR-Cat-EcoRI activation by heat shock was similar to that obtained with the wild-type LTR (Fig. 1C), except that the maximal degree of activation was increased by 2-fold in comparison with the maximal degree of activation of the wild-type LTR. Therefore, palindromic kappa B sites seem to enhance NF-kappa B transactivation ability. We then assessed whether cooperation between SP1 and NF-kappa B was involved in the HIV-1 LTR response to heat shock. To this end, the pLTR-Cat-NcoI mutant was constructed, in which the kappa B and SP1 sites were spaced out by the insertion of a 4-nucleotide sequence so that NF-kappa B and SP1 are located on opposite sides of the DNA helix (Fig. 1E). We observed that the pLTR-Cat-NcoI response to heat shock was similar to that of the wild-type LTR (Fig. 1D). Therefore, cooperation between the kappa B and SP1 sites is not necessary for HIV-1 LTR activation by heat shock. Taken together, these results indicate an intervention of kappa B sites in HIV-1 LTR activation by heat shock since the different modifications of kappa B sites we have tested modulate the HIV-1 LTR response to heat shock.

Heat Shock Activates the NF-kappa B Transcription Factor Independently of Transcriptional and/or Translational Events during the Recovery Period after Heat Stress-- Based on the results presented above, we analyzed whether heat shock was able to activate the NF-kappa B transcription factor itself. To this end, we looked for indices of NF-kappa B activation such as NF-kappa B migration into the nucleus or binding to DNA, transactivation of kappa B-dependent reporter genes, and Ikappa Balpha degradation. The nuclear redistribution of NF-kappa B subunits was analyzed by indirect immunofluorescence. We observed that, during heat shock, HeLa cells became rounded and that the cytoplasmic distribution of the p65/RelA subunit was not modified. In contrast, after 1-5 h of heat shock recovery at 37 °C, the p65 subunit of NF-kappa B redistributed into the nucleus of the cells (Fig. 2A). The same results were obtained with an antibody raised against the p50 subunit of NF-kappa B (data not shown). This experiment showed that heat shock induces the migration of NF-kappa B into the nucleus, but this event seems to solely occur during the recovery period after a heat stress.


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 2.   Heat shock treatment induces p65 migration into the nucleus and binding to kappa B sites. A, HeLa cells were either left untreated or submitted to heat shock treatments at 43 °C for 45 min, for 1.5 h, or for 1.5 h followed by a 1-5-h recovery period at 37 °C. The cells were then fixed and processed for indirect immunofluorescence analysis using an antibody raised against the p65 subunit of NF-kappa B. B, HeLa cells were either left untreated (control (C)) or submitted to heat shock treatments at 43 °C for 90 min (90) or for 90 min followed by a recovery period at 37 °C of 1 h (R1), 3 h (R3), or 5 h (R5). These various treatments were performed in the absence of any drug (black bars) or in the presence of 0.5 µg/ml actinomycin D (dark-gray bars) or 20 µg/ml cycloheximide (light-gray bars) added 5 min before the heat shock treatment. Whole cell extracts were prepared, and NF-kappa B binding to kappa B oligonucleotide was quantified with the Trans-AMTM p65 transcription factor assay kit as described under "Experimental Procedures." The results are presented as -fold stimulation, which was calculated as the ratio of the absorbance of the different samples to that of the control unstressed cells. Specificity of binding was assessed by competition with free oligonucleotide. Twenty pmol of wild-type oligonucleotide prevented the binding of NF-kappa B from the R5 extract to the probe immobilized on the plate (R5 + kappa B). Conversely, 20 pmol of mutated consensus oligonucleotide had no effect on the binding of NF-kappa B from the R5 extract (R5 + mut kappa B). The histogram shown is representative of two identical and independent experiments.

We then quantified NF-kappa B binding to DNA in HeLa cells submitted to heat shock treatments. We observed that p65 binding to kappa B sites was detectable during the first hour of heat shock recovery and increased up to 5 h of recovery at 37 °C (Fig. 2B). Specificity of p65 binding was tested by competition with free kappa B oligonucleotide. Wild-type oligonucleotide competed efficiently for p65 binding after 5 h of heat shock recovery (R5 + kappa B), whereas mutated kappa B oligonucleotide had no effect (R5 + mut kappa B). Monitoring of NF-kappa B binding to DNA was also performed in the presence of 0.5 µg/ml actinomycin D or 20 µg/ml cycloheximide added 5 min before heat shock treatment. These drug concentrations efficiently blocked transcription and translation, respectively (data not shown). We observed that actinomycin D and cycloheximide did not modify the kinetics of NF-kappa B binding to DNA during heat shock recovery. This suggests that no new transcriptional and/or translational events are required during heat shock and heat shock recovery for NF-kappa B activation.

To verify whether NF-kappa B, once in the nucleus, was able to activate kappa B-dependent transcription, we transfected HeLa cells with a plasmid bearing the cat reporter gene under the control of two kappa B elements (p2xkappa B-37TKcat). Cells were then submitted to heat shock treatments, followed by a 24-h recovery period at 37 °C. A small increase in the level of CAT polypeptide driven by p2xkappa B-37TKcat was observed in cells exposed to 41 °C (Fig. 3). This increase was far more pronounced at 42 and 43 °C. Indeed, at 43 °C, stimulation was 3.9-fold; it was more intense than that observed in cells exposed for 1.5 h to 200 µM hydrogen peroxide and represented 65% of that obtained with TNF-alpha treatment. Moreover, the overall kinetics of activation of p2xkappa B-37TKcat was similar to that obtained for the wild-type HIV-1 LTR.


View larger version (16K):
[in this window]
[in a new window]
  		Fig. 3.   Heat shock treatment activates kappa B-dependent gene expression. HeLa cells transiently transfected with the pLTR-Cat-wt (black bars) or p2xkappa B-37TKcat (gray bars) plasmid were either left untreated or submitted to 90-min heat shock treatments performed at 41, 42, 43, and 44 °C. After a 24-h recovery period at 37 °C, the level of CAT enzyme synthesized was analyzed as described under "Experimental Procedures." Presentation of the results is as described in the legend to Fig. 1. A positive control experiment was performed using HeLa cells transfected with the p2xkappa B-37TKcat plasmid and treated for 90 min with 200 µM hydrogen peroxide or with 2000 units/ml TNF-alpha .

NF-kappa B Activation during Heat Shock Recovery Occurs without Any Prior Phosphorylation and Degradation of Ikappa B Subunits-- We next determined whether NF-kappa B translocation into the nucleus after heat shock treatment was induced by Ikappa B degradation. To this end, the level of several inhibitory subunits (Ikappa Balpha , Ikappa Bbeta , and p105) was analyzed by immunoblotting. As shown in Fig. 4A, no degradation or phosphorylation of Ikappa Balpha , Ikappa Bbeta , or p105 could be observed during heat shock treatment performed at 43 °C or during the following recovery period at 37 °C. In contrast, control experiments showed that TNF-alpha treatment induced the phosphorylation and/or degradation of these inhibitory subunits (Fig. 4B). Hence, NF-kappa B migration into the nucleus after a heat stress appears to occur independently of degradation and phosphorylation of its inhibitory subunits.


View larger version (38K):
[in this window]
[in a new window]
  		Fig. 4.   NF-kappa B inhibitory subunits are not degraded during heat shock or during heat shock recovery. A, HeLa cells were either left untreated or submitted to heat shock treatments of different duration (from 10 to 90 min) at 43 °C. Cells were also exposed to 43 °C for 90 min and allowed to recover at 37 °C for 1-5 h. B, HeLa cells were treated with 2000 units/ml TNF-alpha for 3-120 min. Equal amounts of total cellular proteins were separated by 10% SDS-polyacrylamide gel electrophoresis, and the cellular contents of Ikappa Balpha , Ikappa Bbeta , and p105 were investigated by immunoblot analysis using antibodies specific to these proteins as described under "Experimental Procedures."

To confirm that NF-kappa B activation during heat shock recovery is not dependent on the classical signal transduction pathway including Ikappa B phosphorylation by IKK kinase and subsequent degradation, we used dominant-negative mutants of the two kinases that constitute IKK (IKKalpha and IKKbeta ). Double transient transfection of the dominant-negative mutant of IKKalpha (pN-FLAG-CHUK(K44A)) or of IKKbeta (pRK5-IKKbeta (K44A)) with p2xkappa B-37TKcat was performed with HeLa cells. The cells were then submitted to heat shock treatments, and the level of CAT polypeptide synthesized was analyzed. We observed that neither the IKKalpha nor IKKbeta dominant-negative mutant modified the p2xkappa B-37TKcat activation by heat shock (Fig. 5A). In contrast, the IKKbeta dominant-negative mutant and, to a lesser extent, the IKKalpha mutant (as was expected since IKKalpha is not absolutely required for IKK activation (44)) inhibited the stimulated expression of the kappa B-dependent reporter gene after TNF-alpha treatment (Fig. 5A). The same observations were made when a dominant-negative mutant of Ikappa Balpha in which serines 32, 36, 283, 288, 291, 293, and 296 were mutated to alanines (Ikappa Balpha M) was transfected with the p2xkappa B-37TKcat vector (Fig. 5B). Indeed, expression of Ikappa Balpha M did not modify expression of p2xkappa B-37TKcat after a heat stress, whereas it completely abolished its response to TNF-alpha treatment. Therefore, these results show that NF-kappa B activation during heat shock recovery follows a novel signal transduction pathway that does not require phosphorylation and degradation of Ikappa B subunits to release the NF-kappa B transcription factor.


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 5.   Dominant-negative mutants of IKKs or of Ikappa Balpha do not impair NF-kappa B activation by heat shock. A, HeLa cells were transiently transfected with the p2xkappa B-37TKcat plasmid together with either a control plasmid (pUC19; black bars) or an expression vector of a dominant-negative mutant of IKKalpha (pN-FLAG-CHUK(K44A); dark-gray bars) or a dominant-negative mutant of IKKbeta (pRK5-IKKbeta (K44A); light-gray bars). The transfected cells were submitted to 90-min heat shock treatments performed at 41, 42, 43, and 44 °C. A 2-h TNF-alpha (2000 units/ml) treatment was also used as a control. After a 24-h recovery period at 37 °C, cells were analyzed for the level of CAT enzyme synthesized. Presentation of the results is as described in the legend to Fig. 1. B, the same experiment was carried out, but HeLa cells were transiently transfected with the p2xkappa B-37TKcat vector and the pLXSN control plasmid (black bars) or the expression vector of a dominant-negative mutant of Ikappa Balpha (pLXSN-Ikappa Balpha M; gray bars). C, control.

The Pro-oxidant State Generated by Heat Shock Is Dispensable for NF-kappa B Activation-- Most NF-kappa B inducers have been reported to be inhibited by antioxidants such as PDTC and NAC and detoxifying enzymes such as glutathione peroxidase and catalase (29, 30), implying that ROS modulate the signal transduction pathway leading to NF-kappa B activation. Several studies have suggested the involvement of an oxidative stress during heat shock. We therefore tested whether a heat stress could increase the level of ROS and, by using antioxidant drugs such as PDTC and NAC, whether ROS are involved in NF-kappa B activation during heat shock recovery. We performed a kinetic analysis of the in vivo level of ROS during and after heat shock treatment performed at 43 °C. As shown in Fig. 6, an increase in the level of intracellular ROS was detectable already after exposing cells for 1 h at 43 °C. ROS levels continued to increase up to 2 h of heat shock recovery and then decreased to reach the basal level observed in control cells. In contrast, when cells were pretreated with the antioxidant drug PDTC (Fig. 6) or NAC (data not shown), the level of ROS remained unchanged. PDTC and NAC were then used to evaluate the involvement of ROS in NF-kappa B activation during heat shock recovery.


View larger version (29K):
[in this window]
[in a new window]
  		Fig. 6.   Heat shock treatment increases the level of reactive oxygen species. Shown are the results from the in vivo estimation of intracellular ROS levels by fluorescence-activated cell sorter analysis using a hydroethydine fluorescent probe. HeLa cells were either left untreated (gray plots) or submitted to 43 °C heat shock treatments (white plots) for 60 and 90 min. The 90-min heat shock treatment was followed or not by a recovery period of 1, 2, 3, or 4 h at 37 °C. A 4-h treatment with 40 µM menadione was also performed as a positive control for ROS production. The same experiment was performed in the absence of any antioxidant drug or in the presence of 100 µM PDTC. Ethidium bromide (EB) fluorescence was measured as described under "Experimental Procedures." Results are presented as fluorescence histograms.

We first investigated whether these drugs could modulate HIV-1 LTR transcriptional activation or kappa B-dependent gene transcription induced by heat shock. To this end, HeLa cells transiently transfected with the wild-type HIV LTR-Cat (Fig. 7A) or p2xkappa B-37TKcat (Fig. 7B) plasmid were first incubated for 1 h with 100 µM PDTC or 10 mM NAC before being exposed or not to heat shock. The level of CAT polypeptide produced was quantified, and we could observe that PDTC drastically inhibited HIV-1 LTR activation by heat shock (Fig. 7A). Moreover, this compound also completely impaired the heat-induced expression of the p2xkappa B-37TKcat plasmid (Fig. 7B). In contrast, pretreatment with the antioxidant drug NAC did not modify the wild-type HIV LTR-Cat or p2xkappa B-37TKcat plasmid response to heat shock. Hence, these contradictory results prevented us from making a conclusion regarding the involvement or not of a pro-oxidant state in NF-kappa B activation during heat shock recovery.


View larger version (43K):
[in this window]
[in a new window]
  		Fig. 7.   The pro-oxidant state generated by heat shock is dispensable for NF-kappa B activation. A and B, HeLa cells, transiently transfected with either wild-type HIV LTR-Cat or p2xkappa B-37TKcat, respectively, were preincubated for 1 h with either 100 µM PDTC (dark-gray bars) or 10 mM NAC (light-gray bars) or were left untreated (black bars). Cells were then submitted to 90-min heat shock treatments performed at 41, 42, 43, and 44 °C. After a 24-h recovery period at 37 °C, the level of CAT enzyme synthesized was analyzed by enzyme-linked immunosorbent assay. Presentation of the results is as described in the legend to Fig. 1. C, shown are the results for the analysis of p65 cellular localization. HeLa cells pretreated or not for 1 h with 100 µM PDTC were either left at 37 °C or submitted to heat shock treatments at 43 °C for 1.5 h or for 1.5 h followed by a 3-h recovery period at 37 °C. Thereafter, the cells were fixed and processed for indirect immunofluorescence analysis using an antibody raised against the p65 subunit of NF-kappa B.

To determine whether the PDTC effect was due to its antioxidant property in the NF-kappa B transduction pathway or to a possible unspecific role in transcription, we analyzed the level of action of this drug and whether PDTC could alter the migration of NF-kappa B into the nucleus during heat shock recovery. Indirect immunofluorescence analyses were performed with HeLa cells pretreated or not for 1 h with 100 µM PDTC and thereafter submitted to heat shock treatments. We observed the same kinetics of NF-kappa B nuclear migration in the presence and absence of the antioxidant drug (Fig. 7C). These results therefore suggest that PDTC can affect the overall transcription step in an unspecific way and that ROS produced during heat shock are not involved in NF-kappa B activation after a heat stress, as was suggested by the results obtained using cells treated with NAC (Fig. 7, A and B).

Heat Shock Induces p65 and p50 Dissociation from Their Complexing Partners-- To unravel the molecular mechanism responsible for NF-kappa B migration into the nucleus, we analyzed the interactions between NF-kappa B and several of its inhibitors during and after heat shock. To this end, cell extracts from HeLa cells submitted to various heat shock treatments followed or not by a recovery period at 37 °C were used for co-immunoprecipitation studies of p65 and Ikappa Balpha or p100 subunits. As shown in Fig. 8A, p65 was efficiently immunoprecipitated by anti-Ikappa Balpha antibody in control cells. After 90 min of heat shock, decreased co-immunoprecipitation of p65 was observed. This effect was even more pronounced when the experiment was performed with extracts of cells that were allowed to recover for 1 or 3 h at 37 °C after heat shock. In contrast, after a 5-h recovery period at 37 °C, p65 was again slightly co-immunoprecipitated by anti-Ikappa Balpha antibody. These results suggest that the interaction between p65 and Ikappa Balpha begins to be altered after 90 min of heat shock treatment. The dissociation of the complex increased after 1-3 h of heat shock recovery at 37 °C, but was reversible since co-immunoprecipitation of p65 and Ikappa Balpha was again detectable after 5 h of heat shock recovery. The same observations were obtained with p65 and p100 (Fig. 8B) and p65 and p105 (data not shown) co-immunoprecipitations. Hence, heat shock triggers NF-kappa B activation by inducing the dissociation of NF-kappa B from its inhibitory complexing partners during the recovery period that follows a heat stress.


View larger version (58K):
[in this window]
[in a new window]
  		Fig. 8.   Ikappa Balpha or p100 inhibitory subunits dissociate from p65 in HeLa cells recovering from heat shock. HeLa cells were either left untreated (control (C)) or submitted to heat shock treatments at 43 °C for 45 min (45), for 90 min (90), or for 90 min with a recovery period at 37 °C of 1 h (R1), 3 h (R3), or 5 h (R5). Cells were then processed for immunoprecipitation using nonimmune (A and B), anti-Ikappa Balpha (A), or anti-p65 (B) antiserum as described under "Experimental Procedures." Samples were separated by 10% SDS-polyacrylamide gel electrophoresis, and the association of p65 with Ikappa Balpha or with p100 was investigated in immunoblots probed with antibodies raised against either the p65 subunit of NF-kappa B (A) or the p100 inhibitory subunit (B). A positive control sample for the presence of p65 (A) or p100 (B), containing total cellular proteins (Tot), was loaded on the gel. C, the gel filtration analysis of p65 and Ikappa Balpha association during heat shock recovery. HeLa cells were either left untreated (Control) or submitted to a 43 °C treatment for 90 min followed by a 3-h recovery period at 37 °C (43 °C 1h30 + 37 °C 3h). Cell extracts were prepared and applied to gel filtration columns as described under "Experimental Procedures." The fractions eluted from the column were applied to a 10% SDS-polyacrylamide gel, and the fraction content of p65 and Ikappa Balpha was investigated by immunoblot analysis.

To better document the NF-kappa B·Ikappa B complex thermolability observed by co-immunoprecipitation assays, we monitored this complex by gel filtration analysis (Fig. 8C). We observed that, in whole cell extracts of control HeLa cells, the p65 protein was eluted in fractions of ~100-250 kDa and that Ikappa Balpha was recovered in fractions of 40-150 kDa. Hence, p65 and Ikappa Balpha were both recovered in the 100-150-kDa fractions that could represent the NF-kappa B·Ikappa B complex. In contrast, when the same experiment was performed with extracts from HeLa cells submitted to a 90-min heat shock treatment at 43 °C followed by a 3-h recovery period at 37 °C, the p65 subunit was detected in 66-200-kDa fractions, whereas the Ikappa Balpha subunit was recovered solely in 40-kDa fractions. Therefore, p65 and Ikappa Balpha were no longer recovered in the same fractions, suggesting that the p65·Ikappa Balpha complex was disrupted. The same results were obtained when HeLa cells were transiently transfected with the Ikappa Balpha dominant-negative mutant. In this case, we observed a dissociation of the NF-kappa B·Ikappa Balpha M complex (data not shown). Taken together, these results demonstrate that the NF-kappa B·Ikappa B complex is thermolabile, leading NF-kappa B to migrate into the nucleus.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The HIV-1 LTR is transcriptionally activated by various cellular stresses, including heat hock. However, the mechanisms underlying this thermal activation are still obscure. Indeed, a previous study based on deletion analysis of HIV-1 LTR kappa B sites reported a reduced activation of this promoter in heat-shocked U937 promonocytic cells (18). Another report observed an inhibition of heat shock-induced virus activation by pentoxifylline (an NF-kappa B inhibitor) (58). On the other hand, in other studies, we (19) and others (16) did not observe any specific binding of a protein to kappa B motifs in HeLa or Jurkat cells submitted to heat shock treatments. To answer these contradictory results, we performed studies on mutated HIV-1 LTR activation by heat shock. We constructed mutations in kappa B sites of the LTR or modulated the distance between kappa B and SP1 sites because cooperation between kappa B and SP1 sites has been demonstrated in the case of HIV-1 LTR activation by mitogens (59). We observed that spacing SP1 and kappa B sites does not modify the HIV-1 LTR response to heat shock. In contrast, kappa B sites are indispensable for HIV-1 LTR activation by heat stress. Hence, as heat shock induces the accumulation of misfolded proteins, these results suggest that a prolonged fever or pathologies interfering with protein folding are probably inducers of the HIV-1 LTR by way of NF-kappa B transcription factor activation.

We then analyzed NF-kappa B activation by heat shock and observed by immunofluorescence analysis that heat shock treatment induced the migration of p65 and p50 into the nucleus. However, this effect occurred only during the recovery period after the heat stress. The same conclusions were obtained by analysis of NF-kappa B binding to DNA. Moreover, we observed stimulation of kappa B-dependent reporter gene transcription after heat shock (maximal activation at 43 °C for 1.5 h). This stimulation was of similar intensity to that obtained after hydrogen peroxide or TNF-alpha treatment (3.9-fold with heat shock versus 3.1-fold with hydrogen peroxide and 5.8-fold with TNF-alpha ). Hence, heat shock is a very powerful inducer of kappa B-dependent transcription. These results suggest that, during inflammation processes, a persistent fever could be an important event involved in NF-kappa B recruitment. NF-kappa B activation by heat shock is quite intriguing since several studies have reported that heat shock or hsp70 overexpression decreases subsequent NF-kappa B activation by various stressors (60-64). In contrast, Jaattela and co-workers (65, 66) observed that overexpression of hsp70 in mouse fibrosarcoma cells did not influence NF-kappa B activation by TNF-alpha or UV light. However, these reports studied the influence of heat shock on NF-kappa B activation by others stressors and not the direct influence of heat shock on the NF-kappa B transcription factor. In this regard, we observed that NF-kappa B was activated during the recovery period after and not during the heat stress. These results are consistent with two observations: (i) the fact that heat shock transcription factor-1 activation has been associated with NF-kappa B inhibition as if the concomitant activation of both transcription factors was incompatible (67-69); and (ii) the fact that heat shock pretreatment delays (up to 4-6 h) NF-kappa B activation by cytokines (62, 63). Indeed, this delay could be explained by the fact that, as we show in this study, pretreatment by heat shock induced NF-kappa B activation and migration into the nucleus after 1-5 h of recovery at 37 °C. Hence, the transcription factor would not be available for a new induction by other stressors until it is dissociated from DNA and released from the nucleus, thus creating this delay in the NF-kappa B response to a new induction.

Finally, our previous study (19) as well as those of others (16, 64) reported the absence of NF-kappa B binding to DNA in cells submitted to heat shock. This discrepancy can be explained by our present results. The previous studies were performed after mild or short heat treatment and, more importantly, without any recovery period after the heat stress. By quantifying NF-kappa B binding during heat shock or during the recovery period, we demonstrated that the previous conditions are not adequate for NF-kappa B activation. Indeed, we showed that NF-kappa B can bind to DNA solely during the recovery period after a heat stress.

We then analyzed NF-kappa B activation in the presence of transcription (actinomycin D) or translation (cycloheximide) inhibitors. The drug concentrations used have been tested beforehand for their ability to efficiently inhibit transcription or translation. We observed the same kinetics of NF-kappa B binding to DNA in cells submitted to heat shock treatments in the presence or absence of these drugs. Hence, de novo transcription and/or translation events during heat shock or during heat recovery are dispensable for NF-kappa B activation. This suggests that NF-kappa B activation during heat shock recovery results from modification of pre-existing factors. In this respect, further studies of NF-kappa B activation in thermotolerant cells submitted to heat stress will probably provide some clues to the sensor responsible for NF-kappa B mobilization. Indeed, one can ask whether accumulation of misfolded protein could be a stimulus that triggers NF-kappa B activation. In a previous study, we found that NF-kappa B was also activated by amino acid analogs (2); these compounds are structural analogs of natural amino acids rapidly incorporated into newly synthesized polypeptides and therefore induce irreversible aberrant protein conformation. Another drug creating abnormal polypeptides in the cell (puromycin, which induces a premature release of polypeptide chains from ribosomes) can induce transcription of kappa B-dependent genes and NF-kappa B activation.2 But in the case of amino acid analog treatment, the mechanism of NF-kappa B activation is different from the one obtained with heat shock, as it involves Ikappa Balpha degradation by the 26 S proteasome. Hence, a still unknown sensor would be responsible for NF-kappa B activation during heat shock recovery.

As most NF-kappa B inducers seem to involve ROS in their signal transduction pathway, we measured the in vivo level of intracellular ROS during and after a heat stress. We observed a transient increase in the level of ROS produced during heat shock and during the first hours of recovery at 37 °C. These results confirm earlier studies that observed that heat shock pretreatment can sensitize cells or NF-kappa B activation to hydrogen peroxide treatments (22-24). Moreover, it was shown that hydrogen peroxide is able to activate heat shock transcription factor-1 (27, 28). Other studies revealed that in Saccharomyces cerevisiae, oxidative stress is involved in heat shock-induced death (70) and that ROS are intracellular mediators of hyperthermia-induced apoptosis in human HL-60 cells (71). By using the antioxidant drugs PDTC and NAC, we were able to abolish the heat-induced increased level of ROS. Nevertheless, we obtained contradictory results concerning the impairment or not of NF-kappa B activation by heat shock according to whether PDTC or NAC was used, as PDTC, in contrast to NAC, abolished kappa B-dependent gene expression after heat shock. However, PDTC could not impair NF-kappa B migration into the nucleus during the heat recovery period. Therefore, these results suggest that ROS are not involved in NF-kappa B activation during heat shock recovery and that PDTC and NAC could differently affect transactivation of transcription after heat shock. In this respect, recent studies reported that PDTC can have biphasic effects: one conferred by its antioxidant property and the other by its metal (copper/zinc) chelator property (72). Hence, PDTC could also affect, independently of its potential antioxidant role, transcription factor activity by regulating the intracellular zinc and copper ion levels. Therefore, NF-kappa B activation during heat shock recovery does not appear to be dependent on the pro-oxidant state generated by heat-shock.

The finding of NF-kappa B binding to DNA and kappa B-dependent gene transcription prompted us to determine the events responsible for NF-kappa B activation during heat shock recovery. By using dominant-negative mutants of IKKalpha and IKKbeta kinases, we observed that NF-kappa B activation by heat shock was not dependent on prior phosphorylation of its Ikappa B inhibitory subunits. Moreover, immunoblot assays revealed that, at the time point when NF-kappa B migrated into the nucleus after heat shock, its Ikappa Balpha inhibitory subunit was not degraded; this remained true for even longer recovery periods. We obtained the same results when other NF-kappa B inhibitory subunits (i.e. Ikappa Bbeta and p105) were analyzed, demonstrating that NF-kappa B activation by heat shock is independent of Ikappa B degradation. These results were confirmed by the use of the Ikappa Balpha M dominant-negative mutant. Ikappa Balpha M is a super-repressor that cannot be phosphorylated or degraded, but can still interact with NF-kappa B dimers, being a very potent inhibitor of NF-kappa B by keeping it permanently in the cytoplasm. We observed that overexpression of Ikappa Balpha M did not abolish the stimulated expression of p2xkappa B-37TKcat after a heat stress, demonstrating that Ikappa Balpha phosphorylation and degradation are not indispensable for NF-kappa B activation by heat shock. To explain NF-kappa B migration into the nucleus, we thus co-immunoprecipitated p65 and Ikappa Balpha during heat shock and during recovery after heat shock. We observed that p65 and Ikappa Balpha dissociated early during heat shock recovery and re-associated 5 h later. The same held true for the major complexing partners of p65 (and p50), which are p100 and p105. Hence, heat shock induces p50 and p65 dissociation from their inhibitors, allowing possible new matching of NF-kappa B subunits, which then can migrate into the nucleus. These results were strengthened by gel filtration analysis showing that, during heat shock recovery, Ikappa Balpha and p65 were no longer eluted in the same fractions. Hence, heat treatment dissociates Ikappa B from p65/p50 dimers. Moreover, the same dissociation was observed with the dominant-negative mutant of Ikappa Balpha (Ikappa Balpha M). Therefore, these results demonstrate that heat shock activates NF-kappa B by a new mechanism that relies on p65/p50·Ikappa B complex thermolability. One might suggest that heat shock, known to induce unfolded or denatured proteins, could modify the conformation of NF-kappa B inhibitory subunits and their interactions with p65 and p50 since interactions between p65/p50 and its inhibitors are weak (73). The ankyrin domains shared by Ikappa B proteins, p100, and p105 could also be responsible for any destabilization of the NF-kappa B·Ikappa B complex or precursors associated with p65 or p50 after heat shock. But since this mechanism of Ikappa B heat denaturation can hardly explain why the NF-kappa B·Ikappa B complex is dissociated during the heat recovery period and resists elevated temperatures during heat shock, the involvement of a chaperone-mediated dissociation is one hypothesis that will merit further investigations. In this respect, additional studies on the thermolability of the precursor proteins could be informative. p100 and p105 dissociate from p65 and p50. Whether this dissociation occurs in precursors associated with each other, in precursors involved in heterodimers (precursor and p50 or p65), or in heterotrimers (precursor and p50 and p65) (74, 75) merits further investigations and suggests a mechanism involving specific chaperone recognition of the ankyrin domains of Ikappa B proteins and precursors and the specific dissociation of these inhibitors from NF-kappa B.

Hence, we report here a new mechanism of activation of NF-kappa B during heat shock recovery, independent of any de novo transcriptional and/or translational events, with no Ikappa Balpha phosphorylation and degradation. This mechanism relies on the thermolability of Ikappa B subunits that dissociate from NF-kappa B dimers. Therefore, in addition to physiological stressors (ischemia/reperfusion, liver regeneration, hemorrhagic shock), physical stress, or oxidative stress, heat shock must be considered as a stress inducer of NF-kappa B, making this transcription factor a novel regulator of the cellular stress response. However, it is still not known whether the transcription of kappa B-dependent genes during heat shock recovery is beneficial or not for the recovery of cellular functions injured during heat shock.

    ACKNOWLEDGEMENTS

We thank Dominique Guillet for excellent technical assistance, Patrick-A. Baeuerle (Tularik, San Francisco, CA) for the kind gift of the pRK5-IKKbeta (K44A) and pN-FLAG-CHUK(K44A) plasmids, and E. Bates for the pLTR-Cat-PstI plasmid constructions.

    FOOTNOTES

* This work was supported by Association pour la Recherche sur le Cancer Grant 5204 and by the Région Rhône-Alpes (to A.-P. A.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Lab. Stress Oxydant, Chaperons, et Apoptose, Centre de Génétique Moléculaire et Cellulaire, CNRS-UMR5534, Bâtiment Gregor Mendel, 16 rue Dubois, Université Claude Bernard Lyon I, F-69622 Villeurbanne Cedex, France. Tel.: 33-4-72-44-85-95; Fax: 33-4-72-44-05-55; E-mail: Arrigo@univ-lyon1.fr.

Published, JBC Papers in Press, September 14, 2001, DOI 10.1074/jbc.M010821200

2 C. Kretz-Remy and A.-P. Arrigo, unpublished data.

    ABBREVIATIONS

The abbreviations used are: HIV-1, human immunodeficiency virus type 1; LTR, long terminal repeat; TNF-alpha , tumor necrosis factor-alpha ; IKK, Ikappa B kinase; PDTC, pyrrolidine dithiocarbamate; NAC, N-acetyl-L-cysteine; CAT, chloramphenicol acetyltransferase; ROS, reactive oxygen species.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Gendelman, H. E., Phelps, W., Feigenbaum, L., Ostrove, J. M., Adachi, A., Howley, P. M., Khoury, G., Ginsberg, H. S., and Martin, M. A. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 9759-9763[Abstract/Free Full Text]
2. Kretz-Remy, C., Bates, E. E. M., and Arrigo, A.-P. (1998) J. Biol. Chem. 273, 3180-3191[Abstract/Free Full Text]
3. Sarkar, G., and Sommer, S. S. (1990) BioTechniques 8, 404-407[Medline] [Order article via Infotrieve]
4. Regnier, C. H., Song, H. Y., Gao, X., Goeddel, D. V., Cao, Z., and Rothe, M. (1997) Cell 90, 373-383[CrossRef][Medline] [Order article via Infotrieve]
5. Woronicz, J. D., Gao, X., Cao, Z., Rothe, M., and Goeddel, D. V. (1997) Science 278, 866-869[Abstract/Free Full Text]
6. Zandi, E., Rothwarf, D. M., Delhase, M., Hayakawa, M., and Karin, M. (1997) Cell 91, 243-252[CrossRef][Medline] [Order article via Infotrieve]
7. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Science 274, 787-789[Abstract/Free Full Text]
8. Mehlen, P., Kretz-Remy, C., Preville, X., and Arrigo, A.-P. (1996) EMBO J. 15, 2695-2706[Medline] [Order article via Infotrieve]
9. Gaynor, G. (1992) AIDS 6, 347-363[Medline] [Order article via Infotrieve]
10. Bagnarelli, P., Menzo, S., Valenza, A., Manzin, A., Giacca, M., Ancarani, F., Scalise, G., Varaldo, P. E., and Clementi, M. (1992) J. Virol. 66, 7328-7335[Abstract/Free Full Text]
11. Michael, N. L., Vahey, L., Burke, D. S., and Redfield, R. R. (1992) J. Virol. 66, 310-316[Abstract/Free Full Text]
12. Embretson, J., Zupancic, M., Ribas, J. L., Burke, A., Racz, P., Tenner-Racz, K., and Haase, A. T. (1993) Nature 362, 359-362[CrossRef][Medline] [Order article via Infotrieve]
13. Steffy, K., and Wong-Staal, F. (1991) Microbiol. Rev. 55, 193-205[Abstract/Free Full Text]
14. Garcia, J. A., and Gaynor, R. B. (1994) Prog. Nucleic Acids Res. Mol. Biol. 49, 157-196[Medline] [Order article via Infotrieve]
15. Brown, F. L., Tahaoglu, E., Graham, G. J., and Maio, J. J. (1993) Mol. Cell. Biol. 13, 5245-5254[Abstract/Free Full Text]
16. Schreck, R., Rieber, P., and Baeuerle, P.-A. (1991) EMBO J. 10, 2247-2258[Medline] [Order article via Infotrieve]
17. Re, M. C., Furlini, G., and La Placa, M. (1989) J. Virol. Methods 26, 313-317[CrossRef][Medline] [Order article via Infotrieve]
18. Stanley, S. K., Bressler, P. B., Poli, G., and Fauci, A. S. (1990) J. Immunol. 145, 1120-1126[Abstract]
19. Kretz-Remy, C., and Arrigo, A.-P. (1994) FEBS Lett. 351, 191-196[CrossRef][Medline] [Order article via Infotrieve]
20. Burel, C., Mezger, V., Pinto, M., Rallu, M., Trigon, S., and Morange, M. (1992) Experientia (Basel) 48, 629-634
21. Zou, J., Salminen, W. F., Roberts, S. M., and Voellmy, R. (1998) Cell Stress Chaperones 3, 130-141[CrossRef][Medline] [Order article via Infotrieve]
22. Love, J. D., Vivino, A. A., and Minton, K. W. (1986) J. Cell. Physiol. 126, 60-68[CrossRef][Medline] [Order article via Infotrieve]
23. Issels, R. D., Bourier, S., Boning, B., Li, G. C., Mak, J. J., and Wilmanns, W. (1987) Cancer Res. 47, 2268-2274[Abstract/Free Full Text]
24. Sappey, C., Legrandpoels, S., Bestbelpomme, M., Favier, A., Rentier, B., and Piette, J. (1994) AIDS Res. Hum. Retroviruses 10, 1451-1461[Medline] [Order article via Infotrieve]
25. Becker, J., Mezger, V., Courgeon, A. M., and Best-Belpomme, M. (1990) Eur. J. Biochem. 189, 553-558[Medline] [Order article via Infotrieve]
26. Courgeon, A. M., Becker, J., Maingourd, M., Maisonhaute, C., and Best-belpomme, M. (1990) Free Radic. Res. Commun. 9, 147-155[Medline] [Order article via Infotrieve]
27. Jacquier-Sarlin, M., and Polla, B. (1996) Biochem. J. 318, 187-193
28. Jornot, L., Petersen, H., and Junod, A. F. (1997) FEBS Lett. 416, 381-386[CrossRef][Medline] [Order article via Infotrieve]
29. Kretz-Remy, C., Mehlen, P., Mirault, M. E., and Arrigo, A.-P. (1996) J. Cell Biol. 133, 1083-1093[Abstract/Free Full Text]
30. Arrigo, A.-P., and Kretz-Remy, C. (1997) in Free Radicals and the Molecular Biology of Human Diseases (Halliwell, B. , and Aruoma, O., eds) , pp. 183-216, Oxford University Press, Oxford
31. Pahl, H. L. (1999) Oncogene 18, 6853-6866[CrossRef][Medline] [Order article via Infotrieve]
32. Baeuerle, P.-A., and Baltimore, D. (1996) Cell 87, 13-20[CrossRef][Medline] [Order article via Infotrieve]
33. Whiteside, S. T., and Israel, A. (1997) Semin. Cancer Biol. 8, 75-82[CrossRef][Medline] [Order article via Infotrieve]
34. Rice, N. R., MacKichan, M. L., and Israel, A. (1992) Cell 71, 243-253[CrossRef][Medline] [Order article via Infotrieve]
35. Mercurio, F., DiDonato, J. A., Rosette, C., and Karin, M. (1993) Genes Dev. 7, 705-718[Abstract/Free Full Text]
36. Naumann, M., and Scheidereit, C. (1994) EMBO J. 13, 4597-4607[Medline] [Order article via Infotrieve]
37. Arenzana-Seisdedos, F., Thompson, J., Rodriguez, M. S., Bachelerie, F., Thomas, D., and Hay, R. T. (1995) Mol. Cell. Biol. 15, 2689-2696[Abstract]
38. Baldwin, A. S., Jr. (1996) Annu. Rev. Immunol. 14, 649-683[CrossRef][Medline] [Order article via Infotrieve]
39. Zhong, H., SuYang, H., Erdjument-Bromage, H., Tempst, P., and Ghosh, S. (1997) Cell 89, 413-424[CrossRef][Medline] [Order article via Infotrieve]
40. DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., and Karin, M. (1997) Nature 388, 548-554[CrossRef][Medline] [Order article via Infotrieve]
41. Mercurio, F., Zhu, H., Murray, B. W., Shevchenko, A., Bennett, B. L., Li, J., Young, D. B., Barbosa, M., Mann, M., Manning, A., and Rao, A. (1997) Science 278, 860-866[Abstract/Free Full Text]
42. Rothwarf, D. M., Zandi, E., Natoli, G., and Karin, M. (1998) Nature 395, 297-300[CrossRef][Medline] [Order article via Infotrieve]
43. Scheidereit, C. (1998) Nature 395, 225-226[CrossRef][Medline] [Order article via Infotrieve]
44. Karin, M. (1999) Oncogene 18, 6867-6874[CrossRef][Medline] [Order article via Infotrieve]
45. DiDonato, J. A., Mercurio, F., and Karin, M. (1995) Mol. Cell. Biol. 15, 1302-1311[Abstract]
46. Chen, Z. J., Hagler, J., Palombella, V. J., Melandri, F., Scherer, D., Ballard, D., and Maniatis, T. (1995) Genes Dev. 9, 1586-1597[Abstract/Free Full Text]
47. Yaron, A., Gonen, H., Alkalay, I., Hatzubai, A., Jung, S., Beyth, S., Mercurio, F., Manning, A. M., Ciechanover, A., and Ben-Neriah, Y. (1997) EMBO J. 16, 6486-6494[CrossRef][Medline] [Order article via Infotrieve]
48. Yaron, A., Hatzubai, A., Davis, M., Lavon, I., Amit, S., Manning, A. M., Andersen, J. S., Mann, M., Mercurio, F., and Ben-Neriah, Y. (1998) Nature 396, 590-594[CrossRef][Medline] [Order article via Infotrieve]
49. Arenzana-Seisdedos, F., Turpin, P., Rodriguez, M., Thomas, D., Hay, R. T., Virelizier, J. L., and Dargemont, C. (1997) J. Cell Sci. 110, 369-378[Abstract]
50. Sachdev, S., Hoffmann, A., and Hannink, M. (1998) Mol. Cell. Biol. 18, 2524-2534[Abstract/Free Full Text]
51. Bender, K., Gottlicher, M., Whiteside, S., Rahmsdorf, H. J., and Herrlich, P. (1998) EMBO J. 17, 5170-5181[CrossRef][Medline] [Order article via Infotrieve]
52. Li, N., and Karin, M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 13012-13017[Abstract/Free Full Text]
53. Imbert, V., Rupec, R. A., Livolsi, A., Pahl, H. L., Traenckner, E. B.-M., Mueller-Dieckmann, C., Farahifar, D., Rossi, B., Auberger, P., Baeuerle, P.-A., and Peyron, J.-F. (1996) Cell 86, 787-798[CrossRef][Medline] [Order article via Infotrieve]
54. Ghosh, G., van Duyne, G., Ghosh, S., and Sigler, P. B. (1995) Nature 373, 303-310[CrossRef][Medline] [Order article via Infotrieve]
55. Nabel, G., and Baltimore, D. (1987) Nature 326, 711-713[CrossRef][Medline] [Order article via Infotrieve]
56. Stein, B., Kramer, M., Rahmsdorf, H. J., Ponta, H., and Herlich, P. (1989) J. Virol. 63, 4540-4543[Abstract/Free Full Text]
57. Zabel, U., Schreck, R., and Baeuerle, P.-A. (1991) J. Biol. Chem. 266, 252-260[Abstract/Free Full Text]
58. Hashimoto, K., Baba, M., Gohnai, K., Sato, M., and Shigeta, S. (1996) Arch. Virol. 141, 439-447[CrossRef][Medline] [Order article via Infotrieve]
59. Perkins, N. D., Edwards, N. L., Duckett, C. S., Agranoff, A. B., Schmid, R. M., and Nabel, G. J. (1993) EMBO J. 12, 3551-3558[Medline] [Order article via Infotrieve]
60. Wong, H. R., Ryan, M., and Wispe, J. R. (1997) Biochem. Biophys. Res. Commun. 231, 257-263[CrossRef][Medline] [Order article via Infotrieve]
61. Wong, H. R., Ryan, M. A., Menendez, I. Y., and Wispe, J. R. (1999) Cell Stress Chaperones 4, 1-7[Medline] [Order article via Infotrieve]
62. Guzhova, I. V., Darieva, Z. A., Melo, A. R., and Margulis, B. A. (1997) Cell Stress Chaperones 2, 132-139[CrossRef][Medline] [Order article via Infotrieve]
63. Feinstein, D. L., Galea, E., Aquino, D. A., Li, G. C., Xu, H., and Reis, D. J. (1996) J. Biol. Chem. 271, 17724-17732[Abstract/Free Full Text]
64. Curry, H. A., Clemens, R. A., Shah, S., Bradbury, C. M., Botero, A., Goswami, P., and Gius, D. (1999) J. Biol. Chem. 274, 23061-23067[Abstract/Free Full Text]
65. Jaattela, M. (1993) J. Immunol. 151, 4286-4294[Abstract]
66. Simon, M. M., Reikerstorfer, A., Schwarz, A., Krone, C., Luger, T. A., Jaattela, M., and Schwarz, T. (1995) J. Clin. Invest. 95, 926-933
67. Rossi, A., Elia, G., and Santoro, M. G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 746-750[Abstract/Free Full Text]
68. Rossi, A., Elia, G., and Santoro, M. G. (1998) J. Biol. Chem. 273, 16446-16452[Abstract/Free Full Text]
69. Vayssier, M., Favatier, F., Pinot, F., Bachelet, M., and Polla, B. S. (1998) Biochem. Biophys. Res. Commun. 252, 249-256[CrossRef][Medline] [Order article via Infotrieve]
70. Davidson, J. F., Whyte, B., Bissinger, P., and Schiestl, R. H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5116-5121[Abstract/Free Full Text]
71. Katschinski, D. M., Boos, K., Schindler, S. G., and Fandrey, J. (2000) J. Biol. Chem. 275, 21094-21098[Abstract/Free Full Text]
72. Chung, K. C., Park, J. H., Kim, C. H., Lee, H. W., Sato, N., Uchiyama, Y., and Ahn, Y. S. (2000) J. Neurosci. Res. 59, 117-125[CrossRef][Medline] [Order article via Infotrieve]
73. Baeuerle, P.-A., and Baltimore, D. (1988) Science 242, 540-546[Abstract/Free Full Text]
74. Dejardin, E., Bonizzi, G., Bellahcene, A., Castronovo, V., Merville, M. P., and Bours, V. (1995) Oncogene 11, 1835-1841[Medline] [Order article via Infotrieve]
75. Kanno, T., Franzoso, G., and Siebenlist, U. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12634-12638[Abstract/Free Full Text]

Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
C. Cuccurullo, A. Iezzi, M. L. Fazia, D. De Cesare, A. Di Francesco, R. Muraro, R. Bei, S. Ucchino, F. Spigonardo, F. Chiarelli, et al.
Suppression of Rage as a Basis of Simvastatin-Dependent Plaque Stabilization in Type 2 Diabetes
Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2716 - 2723.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y.-Y. Fan, L. H. Ly, R. Barhoumi, D. N. McMurray, and R. S. Chapkin
Dietary Docosahexaenoic Acid Suppresses T Cell Protein Kinase C{theta} Lipid Raft Recruitment and IL-2 Production
J. Immunol., November 15, 2004; 173(10): 6151 - 6160.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
F. Cipollone, M. Fazia, A. Iezzi, G. Ciabattoni, B. Pini, C. Cuccurullo, S. Ucchino, F. Spigonardo, M. De Luca, C. Prontera, et al.
Balance Between PGD Synthase and PGE Synthase Is a Major Determinant of Atherosclerotic Plaque Instability in Humans
Arterioscler. Thromb. Vasc. Biol., July 1, 2004; 24(7): 1259 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
F. Cipollone, A. Iezzi, M. Fazia, M. Zucchelli, B. Pini, C. Cuccurullo, D. De Cesare, G. De Blasis, R. Muraro, R. Bei, et al.
The Receptor RAGE as a Progression Factor Amplifying Arachidonate-Dependent Inflammatory and Proteolytic Response in Human Atherosclerotic Plaques: Role of Glycemic Control
Circulation, September 2, 2003; 108(9): 1070 - 1077.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
A. Parcellier, E. Schmitt, S. Gurbuxani, D. Seigneurin-Berny, A. Pance, A. Chantome, S. Plenchette, S. Khochbin, E. Solary, and C. Garrido
HSP27 Is a Ubiquitin-Binding Protein Involved in I-{kappa}B{alpha} Proteasomal Degradation
Mol. Cell. Biol., August 15, 2003; 23(16): 5790 - 5802.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/47/43723    most recent
M010821200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kretz-Remy, C.
Right arrow Articles by Arrigo, A.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kretz-Remy, C.
Right arrow Articles by Arrigo, A.-P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement